App4Independence (A4i) is a patented, validated digital therapeutic and digital biomarker platform designed to improve outcomes for individuals living with severe mental illnesses (SMIs). Developed as a joint venture between the Centre for Addiction and Mental Health and MEMOTEXT Corporation, A4i supports clinical decision-making, enhances engagement, and identifies relapse risks through the use of ambient, NLP, and engagement data.
A4i is a trans-diagnostic solution, providing cross-cutting applications across conditions such as schizophrenia, psychosis related illness and opioid use disorder. The platform bridges critical gaps in recovery by delivering tools that promote independence, clinician-patient connection, and early risk detection.
Through a mobile app and EMR-integrated portal, A4i offers medication reminders, peer-to-peer support, evidence-based interventions, and innovative features like an ambient hallucination detector and wellness tracking tools. Early research published in PLOS One highlights significant symptom improvements, and ongoing CIHR-funded studies are further exploring A4i’s impact on digital mental health care.
A4i is a trans-diagnostic solution, providing cross-cutting applications across conditions such as schizophrenia, psychosis related illness and opioid use disorder. The platform bridges critical gaps in recovery by delivering tools that promote independence, clinician-patient connection, and early risk detection.
Through a mobile app and EMR-integrated portal, A4i offers medication reminders, peer-to-peer support, evidence-based interventions, and innovative features like an ambient hallucination detector and wellness tracking tools. Early research published in PLOS One highlights significant symptom improvements, and ongoing CIHR-funded studies are further exploring A4i’s impact on digital mental health care.
